相关实验视频

Updated: Dec 5, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

预测肺癌免疫疗法益处的基于血液的生物标志物

D Ross Camidge¹, Erin L Schenk¹

¹Division of Medical Oncology, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.

|October 16, 2020

概括

在转移性非小细胞肺癌中预测免疫疗法的成功是具有挑战性的. 一种新的血液检测提供了一种更准确的方法来识别可能通过PD1/PD-L1治疗实现持久疾病控制的患者.

科学领域:

癌症学
免疫疗法
分子诊断

背景情况:

编程细胞死亡蛋白1 (PD1) /编程死亡配体1 (PD-L1) 免疫疗法是转移性非小细胞肺癌 (NSCLC) 的首要治疗方法.
预测NSCLC免疫疗法反应的生物标志物仍然有限,阻碍了个性化治疗策略.

研究的目的:

在接受免疫治疗的转移性NSCLC患者中开发和验证一种基于血液的新方法来预测持久的疾病控制.
改善患者选择PD1/PD-L1导向疗法.

主要方法:

这项研究报告了一种基于血液的新方法来预测免疫治疗反应.
使用的特定生物标志物和分析技术的详细描述在完整的出版物中.

主要成果:

与现有方法相比,基于血液的新方法在预测持久性疾病控制方面表现出更高的准确性.
这种方法有可能指导NSCLC患者的治疗决策.

结论:

一个新的基于血液的测试可以更准确地预测哪些转移性NSCLC患者将受益于PD1/PD-L1免疫治疗.
这一进步可能会为肺癌患者提供更有效和个性化的治疗选择.

更多相关视频

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.